| Literature DB >> 29416598 |
Qi-Lin Zhang1,2, Bin Xu1, Xiu-Qiang Wang1,2, Ming-Long Yuan3, Jun-Yuan Chen1,2.
Abstract
Amphioxus is used to investigate the origin and evolution of vertebrates. To better understand the characteristics of genome evolution from cephalochordates to Osteichthyes, we conducted a genome-wide pairwise comparison of protein-coding genes within amphioxus (a comparable group) and parallel analyses within Osteichthyes (two comparable groups). A batch of fast-evolving genes in each comparable group was identified. Of these genes, the most fast-evolving genes (top 20) were scrutinized, most of which were involved in immune system. An analysis of the fast-evolving genes showed that they were enriched into gene ontology (GO) terms and pathways primarily involved in immune-related functions. Similarly, this phenomenon was detected within Osteichthyes, and more well-known and abundant GO terms and pathways involving innate immunity were found in Osteichthyes than in cephalochordates. Next, we measured the expression responses of four genes belonging to metabolism or energy production-related pathways to lipopolysaccharide challenge in the muscle, intestine or skin of B. belcheri; three of these genes (HMGCL, CYBS and MDH2) showed innate immune responses. Additionally, some genes involved in adaptive immunity showed fast evolution in Osteichthyes, such as those involving "intestinal immune network for IgA production" or "T-cell receptor signaling pathway". In this study, the fast evolution of immune-related genes in amphioxus and Osteichthyes was determined, providing insights into the evolution of immune-related genes in chordates.Entities:
Keywords: Immunology; Osteichthyes superclass; cephalochordates; fast evolution; immune-related genes; protein-coding genes
Year: 2017 PMID: 29416598 PMCID: PMC5787515 DOI: 10.18632/oncotarget.22749
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Figure 1Phylogenetic tree and evolutionary time frame for chordates
Adapted from Yue et al. and Venkatesh et al. [2, 7].
Means of genome-wide Ka, Ks, and Ka/Ks values and statistics of GO and KEGG terms for three comparable groups.
| All genes | Particularly fast-evolving genes (top 5% identified by Ka) | Fast-evolving genes (top 10% identified by Ka) | Particularly fast-evolving genes (top 5% identified by Ka/Ks) | Fast-evolving genes (top 15% identified by Ka/Ks) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Bf vs Bb | Dr vs Lc | Dr vs Tr | Bf vs Bb | Dr vs Lc | Dr vs Tr | Bf vs Bb | Dr vs Lc | Dr vs Tr | Bf vs Bb | Bf vs Bb | |
| 0.3033 | 0.2826 | 0.2042 | 1.0338 | 0.6965 | 0.5756 | 1.0174 | 0.6341 | 0.5003 | 1.0307 | 1.0174 | |
| 0.8714 | 3.2931 | 3.3977 | 0.8963 | 0.9459 | 0.8936 | 0.9459 | |||||
| 0.3162 | 1.1584 | 1.0804 | 1.1586 | 1.0804 | |||||||
| T# | 130 | 21 | 32 | 227 | 23 | 61 | 138 | 166 | |||
| N* | 87 | 22 | 25 | 147 | 20 | 40 | 92 | 112 | |||
| N/T (%) | 66.92 | 95.65 | 78.13 | 64.76 | 95.24 | 65.57 | 66.67 | 67.47 | |||
| K& | 20 | 31 | 37 | 19 | |||||||
# T: Total number of GO terms for which the particular gene sets are significantly enriched; *N: Number of immune-related GO for which the particular gene sets are significantly enriched; &K: Number of KEGG terms for which the particular gene sets are significantly enriched. Branchiostoma floridae vs B. belcheri (Bf vs Bb); Danio rerio vs. Latimeria chalumnae (Dr vs Lc); D. rerio vs. Takifugu rubripes (Dr vs Tr).
Top 20 most fast-evolving genes in each of three comparable groups.
| Gene description ( | Gene name | |
|---|---|---|
| Iron-sulfur cluster assembly scaffold protein IscU | 1.5847 | ISCU |
| Ultraviolet-B receptor UVR8 | 1.5294 | UVR8 |
| Toll-like receptor 4 | 1.4546 | TLR4 |
| Interleukin-17 receptor D | 1.4422 | IL17D |
| DNA-directed RNA polymerase II subunit RPB7 | 1.4417 | POLR2G |
| Vacuolar ATPase assembly integral membrane protein VMA21 | 1.4351 | VMA21 |
| Complement component C1q receptor | 1.4237 | CD93 |
| E3 ubiquitin-protein ligase TRIM71 | 1.4069 | TRIM71 |
| Transforming growth factor-beta-induced protein | 1.3847 | TGFBI |
| Complement factor H-related protein 1 | 1.3837 | CFHR1 |
| UBA-like domain-containing protein 2 | 1.3790 | UBALD2 |
| Interferon regulatory factor 4 | 1.3760 | IRF4 |
| Thymosin beta-10 | 1.3751 | TMSB10 |
| Polycomb group RING finger protein 1 | 1.3662 | PCGF1 |
| Astrocytic phosphoprotein PEA-15 | 1.3645 | PEA15 |
| Cytochrome c2 | 1.3574 | C2 |
| TNF receptor-associated factor 6 | 1.3521 | TRAF6 |
| Transmembrane protein 203 | 1.3421 | TMEM203 |
| Sperm-associated antigen 7 | 1.3412 | SPAG7 |
| NACHT, LRR and PYD domains-containing protein 3 | 1.3376 | NLRP3 |
| Mucin-1 | 0.9894 | MUCIN1 |
| Chromogranin B | 0.9799 | CHGB |
| Macrophage receptor with collagenous structure | 0.9249 | MARCO |
| Podocalyxin-like 2 | 0.8992 | PODXL2 |
| Meis homeobox 1 b | 0.8945 | MEIS1 |
| Eph receptor A3 | 0.8915 | EPHA3 |
| MACRO domain containing 1 | 0.8908 | MACROD1 |
| Notch 2 | 0.8753 | NOTCH 2 |
| Complement factor H like 4 | 0.8690 | CFHL4 |
| Spalt-like transcription factor 1a | 0.8690 | SALL1A |
| Myelin transcription factor 1a | 0.8648 | MYT1A |
| CD79a molecule, immunoglobulin-associated alpha | 0.8630 | CD79a |
| Mitogen-activated protein kinase kinase kinase 5 | 0.8609 | MAP3K5 |
| Interleukin 2 receptor, beta | 0.8536 | IL2RB |
| Hematopoietic death receptor | 0.8523 | HDR |
| NLR family, CARD domain containing 3 | 0.8498 | NLRC3 |
| Calcitonin/calcitonin-related polypeptide, alpha | 0.8456 | CALCA |
| Caspase 8 associated protein 2 | 0.8445 | CASP8AP2 |
| MAP7 domain containing 2a | 0.8443 | MAP7D2A |
| Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta | 0.8405 | NFKBIZ |
| Interleukin 13 receptor, alpha 1 | 1.1271 | IL13RA1 |
| lymphotoxin alpha (TNF superfamily, member 1) | 0.9460 | LTA |
| Telomeric repeat binding factor a | 0.8847 | TERFA |
| Secreted phosphoprotein 1 | 0.8533 | SPP1 |
| Cytokine receptor family member b2 | 0.8403 | CRFB2 |
| Neurotrophic tyrosine kinase, receptor, type 2a | 0.8241 | NTRK2A |
| Serine/threonine/tyrosine interacting-like 1 | 0.8119 | STYXL1 |
| Interferon-induced protein with tetratricopeptide repeats 15 | 0.8108 | IFIT15 |
| Interleukin 20 receptor, alpha | 0.8070 | IL20RA |
| CD79b molecule, immunoglobulin-associated beta | 0.8065 | CD79B |
| Polymerase (DNA directed) kappa | 0.8056 | POLK |
| Interleukin 21 | 0.8042 | IL21 |
| Cytokine receptor family member b1 | 0.7987 | CRFB1 |
| Interleukin 15, like | 0.7981 | IL15L |
| Interleukin-1 family member A | 0.7902 | IL1FMA |
| Interleukin 2 receptor, beta | 0.7902 | IL2RB |
| Interleukin 12a | 0.7884 | IL12A |
| Collagen, type IV, alpha 3 | 0.7844 | COI4A3 |
| Threonine synthase-like 2 | 0.7801 | THNSL2 |
| Cytokine receptor family member b6 | 0.7744 | CRFB6 |
Figure 2Top 20 KEGG pathways enriched by the top 10% Ka (A) and the top 15% Ka/Ks (B) for Branchiostoma belcheri vs B. floridae in descending order of the P-values. A low P-value indicates a high level of enrichment.
Figure 3Top 20 KEGG pathways enriched by the top 10% Ka for Latimeria chalumnae vs Danio rerio (A) and for Takifugu rubripes vs D. rerio (B) in descending order of the P-values.
Figure 4Expression profiles of HMGCL, SAT2, CYBS and MDH2 in the different tissues (skin, intestine and muscle) of Branchiostoma belcheri challenged with LPS
HMGCL in the skin, SAT2 in the intestine, and CYBS and MDH2 in the muscle Expression level at each time point is shown as the mean ± SD (n = 3). “**” highly significant difference compared with the control, P < 0.01; “*”significant difference, P < 0.05.